by H Ali | Nov 28, 2025 | Clinician Newsletters, Newsletters
Welcome to the 2025 update. BADBIR is a world leading pharmacovigilance Register for psoriasis built through the collective effort of the UK and Ireland dermatology community. While we prepare an accessible version of the update available here, you can download a...
by H Ali | Sep 15, 2025 | News
We are pleased to announce that BADBIR will once again be present at the BDNG Annual Conference in Harrogate this year, between 30th September – 2nd October. We will have a stand in the exhibition hall all three days with several members of the BADBIR team...
by H Ali | Jul 18, 2025 | News
Please be aware that BADBIR cannot accept any new registrations at baseline for patients starting Taltz after 31st July. Participants must have started treatment and provided consent before 1st August to be accepted. If participants signed consent and commenced Taltz...
by H Ali | Jul 18, 2025 | Uncategorised
Since the patent for Stelara (ustekinumab) expired in 2024, there are now four ustekinumab biosimilars available in the UK: Pyzchiva Steqeyma Uzpruvo Wenzela We expect that the majority of the patients on BADBIR who are currently taking Stelara will switch to one of...
by H Ali | May 29, 2025 | News
We will be at the BAD Annual Meeting in Glasgow from the 1st to the 3rd July – come visit us at our stand! You can also attend one of our talks: – Tuesday, 1st July at 10:30 – Prof Warren & Dr Oras Alabas – Hot Topics – Update on new...
Recent Comments